Table of Contents
What changed
Income from operating activities rose 12.6% to $181.0m and profit before tax rose 13.9% to $172.1m, carrying NPAT up 12.0% to $163.5m. Operating cash flow grew faster than earnings, up 17.5% to $196.8m, and the cash balance climbed to $128.3m from $89.0m at HY22. Against the FY22 anchor, however, total assets fell 10.5% to $8.6b and equity fell 7.8% to $7.3b, while total liabilities dropped 23.1%. Gross borrowings held flat at $10.0m, leaving a net cash position of $118.3m. The interim dividend was lifted to 11.0 cps from 10.0 cps.
What matters
- Income versus portfolio value are moving in opposite directions. Investee dividend income is compounding (revenue +12.6%, PBT +13.9%), but the portfolio itself is smaller than at FY22, with equity down $613.7m. For an LIC, that divergence is the central read: distributable earnings are strong even as NAV has de-rated.
- Cash conversion is robust. OCF of $196.8m exceeded NPAT of $163.5m (≈120%), and cash rose $39.2m versus HY22 despite an unchanged debt stack. That supports the step-up in the interim dividend.
- Payout discipline is intact. Interim DPS of 11.0 cps implies a payout ratio of ~83% of NPAT, essentially unchanged from HY22's 83.9%. The dividend lift is funded from higher underlying income, not from a higher distribution rate.
Expectations
No forward guidance or quantitative target was disclosed. On shape: HY22 represented 44.6% of FY22 revenue and 40.5% of FY22 NPAT, implying a modestly second-half-weighted pattern. Annualising HY23 revenue gives $362.0m, broadly in line with FY22's $360.6m, but if the second-half skew repeats, full-year income would exceed FY22. The release does not support an inference about whether portfolio market value recovers; it only supports the income trajectory.
Quality of result
The earnings look durable in composition. The PBT-to-NPAT growth gap is only 1.9pp, with the effective tax rate rising from 3.4% to 4.9% — not a material distortion. No non-recurring items were flagged and no non-GAAP reconciliation was required. Operating cash conversion improved rather than deteriorated, and the rise in cash is genuine rather than working-capital-assisted in any material sense evident from the disclosure. The caveat is structural: as an LIC, revenue is a function of investee dividend flows, so durability ultimately depends on those investee payout policies continuing.
Unresolved
- What share of the 12.6% income lift came from special dividends versus ordinary dividends from portfolio holdings?
- What is HY23 NTA per share, and how does it compare with the $7.76 HY22 reference point after the 10.5% asset decline?
- Was any portfolio turnover material enough to influence realised gains or the tax line?
- Is the $39.2m rise in cash a deliberate liquidity build or a residual of timing around dividend receipts and payments?
This briefing cannot assess underlying portfolio composition changes, realised-versus-unrealised gain split, or manager commentary on outlook, none of which were present in the extracted materials.
Key metrics
| Metric | HY23 | HY22 | Change |
|---|---|---|---|
| Revenue | $181.0m | $160.7m | +12.6% ↑ |
| Net profit after tax | $163.5m | $146.0m | +12.0% ↑ |
| Net cash inflow from operating activities | $196.8m | $167.5m | +17.5% ↑ |
| Profit before tax | $172.1m | $151.2m | +13.9% ↑ |
| Cash and cash equivalents | $128.3m | $89.0m | +44.1% ↑ |
| Total assets | $8.6b | $9.6b | -10.5% ↓ |
Reference: annolyse.ai/briefings/afi-hy23
Analytical metrics
| Metric | HY23 | HY22 | Context |
|---|---|---|---|
| PBT growth | +13.9% | — | — |
| Effective tax rate | 4.9% | 3.4% | — |
| Net debt | −$118.3m | −$79.0m | −$39.2m |
| Gross borrowings | $10.0m | $10.0m | +$0.0m |
| Payout ratio vs NPAT | 83.0% | — | — |
| ROE (annualised) | 2.2% | 2.0% | Strengthening |
| HY22 share of FY22 revenue | 44.6% | — | Other half was 55.4% |
| HY22 share of FY22 NPAT | 40.5% | — | Other half was 59.5% |
| Profit from continuing operations | $163.7m | — | — |
Reference: annolyse.ai/briefings/afi-hy23
This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.